The acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further strengthening a collaboration that has spanned more than a decade.
Novonesis has completed its acquisition of Australian biotechnology company MicroBioGen after receiving all regulatory approvals.
The deal builds on Novonesis’ 2013 investment and existing 23 per cent stake, deepening a collaboration of more than a decade.
Novonesis says MicroBioGen’s yeast-breeding expertise can support biosolutions beyond bioethanol across multiple industries.
“With this acquisition, we strengthen our yeast and R&D expertise and take another step toward delivering on our 2030 strategy. We are pleased to welcome our new colleagues to Novonesis and bring these capabilities into our company, where we can unlock its broader potential. The acquisition reflects our disciplined approach to investing for growth,” says Ester Baiget, CEO of Novonesis.
As a pure-play biology company, Novonesis draws on deep expertise in microbiology and industrial fermentation. MicroBioGen’s advanced yeast-breeding capabilities complement this scientific foundation, creating opportunities to develop new biosolutions for customers across multiple industries.
“MicroBioGen has been a highly valued partner for more than a decade, and today marks the next step in that journey. By bringing together our complementary expertise and technologies, we can further strengthen our yeast capabilities and continue developing the biosolutions our customers need. We see potential for applications not only in bioethanol but also across other industries we serve, as is the case with many of our technologies,” says Claus Crone Fuglsang, Chief Scientific Officer at Novonesis.
Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations.
Note: The headline, insights, and image of this press release may have been refined by the ALCHEMPro staff; the rest of the content remains unchanged.
ALCHEMPro News Desk (JP)
